NATAN DAVID
Transaction: 08/07/2026
BUY
Change
+58,300
Price
Not reported
Filing
08/11/2026
Type
BUY
Sunshine Biopharma, Inc.
SBFM • Drug Manufacturers - Specialty & Generic
$1.14
▲ +0.03 (+2.70%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.09M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.04Healthy liquidity · 4.17Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:41 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.14
Change2.70%
Shares Out952.43K
Market Cap$1.09M
Enterprise Value$-12.66M
52W Range1.10 - 24.30
Beta1.31
P/E-0.18
P/S0.07
P/B0.04
P/FCF-0.21
EV/Sales-0.76
Price$1.14
Change2.70%
Shares Out952.43K
Market Cap$1.09M
Enterprise Value$-12.66M
52W Range1.10 - 24.30
Beta1.31
P/E-0.18
P/S0.07
P/B0.04
P/FCF-0.21
EV/Sales-0.76
EV/EBITDA2.23
EV/FCF2.45
Earnings Yield-570.33%
FCF Yield-475.82%
Dividend Yield0.00%
Gross Margin32.84%
Oper. Margin-12.34%
Profit Margin-16.46%
Debt/Eq0.04
Current Ratio4.17
Quick Ratio2.08
Volume181.58K
Avg Volume1.66M
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.04Healthy liquidity · 4.17Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 1 analyst votes · 2026-09-05
100/100
Bullish
Bullish
1
Hold
0
Bearish
0
Insider Transactions
Recent executive and insider activity
⚠ 2 high-volume insider sells detected
NATAN DAVID
Transaction: 04/14/2026
BUY
Change
+100,000
Price
Not reported
Filing
04/14/2026
Type
BUY
Roy Michel
Transaction: 01/13/2025
OTHER
Change
0
Price
Not reported
Filing
01/21/2025
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| NATAN DAVID | BUY | +58,300 | Not reported | 08/07/2026 | 08/11/2026 |
| NATAN DAVID | BUY | +100,000 | Not reported | 04/14/2026 | 04/14/2026 |
| Roy Michel | OTHER | 0 | Not reported | 01/13/2025 | 01/21/2025 |
| Slilaty Steve N. | BUY | +100,000 | $0.10 | 03/04/2024 | 03/05/2024 |
| Slilaty Steve N. | BUY | +20,000 | $0.10 | 02/08/2024 | 02/12/2024 |
| Beaudoin Marc | OTHER | 0 | Not reported | 01/26/2024 | 02/09/2024 |
| Sebaaly Camille | BUY | +30,000 | $0.76 | 11/30/2022 | 12/02/2022 |
| Chamoun Malek | SELL | 0 | Not reported | 10/20/2022 | 10/26/2022 |
| Sebaaly Camille | BUY | +25,000 | $1.22 | 06/03/2022 | 06/06/2022 |
| Slilaty Steve N. | SELL | -990,000 | $0.10 | 02/18/2022 | 02/22/2022 |
| Keller Andrew Mark | SELL | 0 | Not reported | 02/10/2022 | 02/18/2022 |
| NATAN DAVID | SELL | 0 | Not reported | 02/10/2022 | 02/18/2022 |
| Kiderchah Rabi | SELL | 0 | Not reported | 10/31/2021 | 12/16/2021 |
| Kish James Daniel | OPTION | 0 | Not reported | 10/31/2021 | 12/14/2021 |
| TELSEY ANDREW I | SELL | 0 | Not reported | 10/31/2021 | 12/09/2021 |
| Sebaaly Camille | BUY | +20,000,000 | $0.00 | 01/06/2021 | 02/16/2021 |
| Slilaty Steve N. | BUY | +20,000,000 | $0.00 | 01/06/2021 | 02/16/2021 |
| MERZOUKI ABDERRAZZAK | BUY | +20,000,000 | $0.00 | 01/06/2021 | 02/16/2021 |
| Sebaaly Camille | SELL | -323,673 | $0.00 | 12/31/2019 | 07/15/2020 |
| Sebaaly Camille | BUY | +1,300,000 | $0.00 | 12/19/2019 | 07/15/2020 |